NCCN clinical practice guidelines in oncology: prostate cancer.

By J. Mohler, R. Bahnson, B. Boston, J. E. Busby, A. D'Amico, J. Eastham, C. Enke, D. George, E. Horwitz, R. Huben and 15 more. The Journal of the National Comprehensive Cancer Network, 2010

1,022 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/2cea6108b57b991e74bdd6f89ab17648c7abd9c4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Antoniou
2. D. Easton
3. M. Tischkowitz
4. S. Peock
5. D. Frost
6. Z. Kote-Jarai
7. A. Ardern-jones
8. R. Eeles

Citations in the corpus

• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. (2013, methodology): “On the basis of previous literature, Gleason scores were categorized into a total score of 6, 7, and 8, according to the grade of anaplasia.(21) OS time was calculated from the date of PCa diagnosis until date of death from any cause or censored at the last follow-up.”